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Isabel Vila, BSN,* and Nuno Sousa, PhD, MDÞþ
Background: Cardiovascular disease and dementia are growing medi-
cal and social problems in aging societies. Appropriate knowledge of
cardiovascular disease and cognitive decline risk factors (RFs) are critical
for global CVR health preventive intervention. Many epidemiological
studies use case definition based on data collected/measured in a single
visit, a fact that can overestimate prevalence rates and distant from clinical
practice demanding criteria. Portugal displays an elevated stroke mortality
rate. However, population’s global CV risk characterization is limited,
namely, considering traditional/nontraditional RF and new intermediate
phenotypes of CV and renal disease. Association of hemodynamic vari-
ables (pulse wave velocity and central blood pressure) with global CVR
stratification, cognitive performance, and kidney disease are practically
inexistent at a dwelling population level.
Study Design and Methods: After reviewing published data, we de-
signed a population-based cohort study to analyze the prevalence of these
cardiovascular RFs and intermediate phenotypes, using random sampling
of adult dwellers living in 2 adjacent cities. Strict definition of phenotypes
was planned: subjects were observed twice, and several hemodynamic and
other biological variables measured at least 3 months apart.
Results: Three thousand thirty-eight subjects were enrolled, and exten-
sive data collection (including central and peripheral blood pressure, pulse
wave velocity), sample processing, and biobank edification were carried
out. One thousand forty-seven cognitive evaluations were performed.
Conclusions: Seeking for CV risk reclassification, early identification
of subjects at risk, and evidence of early vascular aging and cognitive
and renal function decline, using the strict daily clinical practice criteria,
will lead to better resource allocation in preventive measures at a pop-
ulation level.
Key Words: blood pressure, cardiovascular risk, chronic kidney
disease, cognitive impairment, arterial stiffness, early vascular aging
(J Investig Med 2014;62: 813Y820)
G rowing scientific evidence progressively changed clinicalmanagement of cardiovascular (CV) risk patients. Currently,
the CV risk profile of the subject based on a wider picture
of concurrent CV risk factors (CVRFs) must be considered. Tai-
loring CVRF control to the CV risk profile of the individual is,
therefore, the current recommended strategy to prevent and delay
the establishment of CV disease (CVD) and the progression on
the CV continuum, as defined by Dzau1,2 and recently reviewed
by O’Rourke et al.3 Still, and despite growing knowledge and
adjustment of clinical management of CVRFs, death by CVD is
still increasing and the leading cause of mortality in the world.4
Effective prevention of CVRFs and CVD is dependent on the
establishment of appropriate public health policies and health care
resource allocation based on the correct knowledge of the local
epidemiological reality. Therefore, it is of relevance to gather in-
formation related to the following questions: Is the Portuguese
reality concerning CVD and cognitive decline similar to what
has been registered in different European countries? If not, can
knowledge gathered in populations with different CVD manifes-
tations and risk profile open new doors in CVD research and
be applicable elsewhere? Is there a correct knowledge concerning
the prevalence of the different CVRFs and inherent risk profile?
Are there different contributors to the establishment of CVD
and dementia? Can new concepts on risk of CVD development
be applied to recognize subjects at risk?
To answer these questions, we propose to carry out an epi-
demiological study evaluating the CV risk profile of the pop-
ulation of 2 adjacent cities in the north of Portugal, not only
analyzing the prevalence of traditional and nontraditional RFs,
but also identifying in this population the prevalence of new in-
termediate markers of risk and/or new intermediate phenotypic
expressions of progression to CVD or target-organ disease (heart,
brain, and kidney). Ultimately, we seek to find a global CV risk
and subclinical CVD picture of the population, which will guide
future clinical search of individuals at risk through early
reclassification of their CVand cognitive risk status.
Objectives
A cohort study was designed to evaluate a representative
sample of the adult population of 2 adjacent cities in the north of
Portugal: Guimara˜es and Vizela. Using a different methodology
of approach and strict definition of criteria, the main objectives of
this study are as follows:
1. to establish the prevalence of traditional (hypertension,
diabetes, dyslipidemia, overweight, tobacco use, metabolic
syndrome) and nontraditional (chronic kidney disease
[CKD], hyperuricemia, salt consumption, abdominal obe-
sity) CVRFs.
2. to evaluate the normal distribution of pulse wave ve-
locity (PWV) and central blood pressure (BP) values in the
ORIGINAL ARTICLE
Journal of Investigative Medicine & Volume 62, Number 5, June 2014 813
From the *Center for the Research and Treatment of Arterial Hypertension
and Cardiovascular Risk, Internal Medicine Department, Guimara˜esYCentro
Hospitalar do Alto Ave, and †Life and Health Science Research Institute
(ICVS), School of Health Science, University of Minho; ‡ICVS/3B’sYPT
Government Associate Laboratory, Braga/Guimara˜es; and §Departamento
de Estudo de Populac¸o˜es, Instituto de Cieˆncias Biome´dicas Abel Salazar,
Universidade do Porto, Porto, Portugal.
Received November 4, 2013, and in revised form January 23, 2014.
Accepted for publication January 23, 2014.
Reprints: Pedro Guimara˜es Cunha, MD, Center for the Research and Treatment
of Arterial Hypertension and Cardiovascular Risk, Servic¸o de Medicina
Interna do Hospital de Guimara˜es, Centro Hospitalar do Alto Ave, Life and
Health Science Research Institute (ICVS), University of Minho, Rua dos
Cutileiros, Creixomil, 4810, Guimara˜es. Portugal.
E-mail: pedrogcunha@netcabo.pt; pedrocunha@ecsaude.uminho.pt.
All authors declare no conflict of interest.
Supplemental digital content is available for this article. Direct URL citation
appears in the printed text and is provided in the HTML and PDF versions
of this article on the journal’s Web site (www.jinvestigativemed.com).
Copyright * 2014 by The American Federation for Medical Research
ISSN: 1081-5589
DOI: 10.231/JIM.0000000000000069
Copyright © 2014 American Federation for Medical Research. Unauthorized reproduction of this article is prohibited.
population and establish the prevalence of arterial stiffness
and early vascular aging (EVA) signs.
3. to define the prevalence of established CVand renal disease
and evaluate the existence and extension of target-organ
damage (TOD) (arterial bed, heart, kidney, and brain) in
subjects with added CV risk.
4. to establish the population’s risk profile (using the European
Society of Hypertension [ESH]5 risk classes and the SCORE
[Systematic COronary Risk Evaluation] classification)6,7 and
identify the fraction that would be reclassified in terms of risk
assessment due to the determination of EVA syndrome and/or
subclinical organ damage (as evaluated by arterial stiffness and
kidney function studies), allowing for a precocious clinical
intervention or treatment intensification.
5. to evaluate the existence of an association between signs of
macrovascular disease (arterial stiffness) with both different
subtypes of metabolic syndrome and the accelerated de-
velopment of cognitive deterioration.
MATERIALS AND METHODS
Study Consortium and Ethical Issues
To achieve the proposed goals, a protocol of collaboration was
established between 3 different institutions: The Centro Hospitalar
do Alto Ave (hospital reference center); The Agrupamento de
Centros de Sau´de (ACESYGroup of Community Primary Health
Care) Guimara˜es/Vizela (coordinating the activity of all the 13
primary community health care centers [PCHCCs] that operate in
the area); and the Life and Health Sciences Research Institute,
Minho University. The project was submitted to and approved not
only by the ethics committee of the Administrac¸a˜o Regional de
Sau´de do Norte (Health Administration for the North Region) but
also by the National Commission for Data Protection.
Study Type, Sample Selection, and Subject
Recruitment
We designed a cohort study (prepared for a longitudinal
evaluation) evaluating a representative sample of the population
of the 2 previously mentioned cities. We did not intend to obtain
data that would be extrapolated to the national population as
some characteristics of the population of these 2 cities (age and
socioeconomic distribution) are different from the rest of the
country (Supplemental Table 1, Supplemental Digital Content 1,
http://links.lww.com/JIM/A21).
There is no direct clinical intervention by the investigators,
and no invasive procedure beyond blood sample collection in a
peripheral venous access was programmed.
Participants have been randomly appointed through a ran-
dom sampling method performed based on the list of citizens
currently living in Guimara˜es and Vizela. In Portugal, every
citizen must be registered in the PCHCC of his/her residence
area. We first compared the information concerning the char-
acteristics of citizens living in Guimara˜es/Vizela (INE, 2006)
and the same information of those with an actual registry in one
of the primary care facilities operating in the 2 cities, finding
that the difference between both lists was inferior to 2%, therefore
allowing us to state that, for practical use, the populations enrolled
in PCHCC and living in Guimara˜es/Vizela are virtually the same.
Portugal, like several European countries, does not collect infor-
mation on ethnicity of the resident population; the overwhelming
majority of its population is white. Ethnicity was not therefore
considered as a factor in the study. Foreign residents in these
2 cities represent 3.6% of the population, and most of them are
of European origin (Supplemental Table 2, Supplemental Digital
Content 1, http://links.lww.com/JIM/A21).
Bearing in mind the available information regarding the
characteristics of the population of Guimara˜es and Vizela and
the characteristics that we intend to study, a representative
sample of that adult population (Q18 years of age) stratified by
age was defined previewing the necessity of including 4000
individuals (95% confidence interval with an estimation error
inferior to 2%, considering a 25% safety margin to cope with
nonadherence and dropout rate between visits). At the same
time, and anticipating a higher nonadherence and dropout rates
on younger and professionally active individuals, the number
of randomized individuals to enroll was divided unevenly
according to their age (2000 individuals would be G35 years of
age, 1000 subjects would have 35 and 65 years of age, and 1000
subjects would be 965 years). Individuals registered in the local
PCHCC and corresponding to the stratification characteristics
were randomized as previously mentioned. Family doctors in
charge of the randomized individuals have then been contacted,
explained the goals of the project, and equipped with informa-
tion materialVthey were afterward responsible to contact the
subjects and obtain their written consent form to participate.
It was therefore clear that only randomly assigned subjects
could be enrolled and that no volunteers or physician-selected
subjects would be included. If the subject refused, the general
practitioner could not replace him/her with a volunteer or with
someone from his/her practice. Only randomized subjects were
accepted. Pregnant women and subjects unable to move or
bedridden were excluded.
Criteria Definition
In accordance with the strict methodology already de-
scribed, the following criteria to define conditions were chosen:
1. blood pressure categorization and hypertension definition
according to the ESH 2007 guidelines5 or whenever a
subject was taking antihypertensive medication; 3 mea-
surements under recommended conditions were taken using
a validated device (Omron 705-IT; OMRON Healthcare
Europe B.V., Hoofddorp, The Netherlands), and the mean
of the last 2 measurements was used;
2. diabetes mellitus and glucosemetabolism conditions according
to the American Diabetes Association,8 or whenever a subject
was taking antidiabetic medication;
3. dyslipidemia, metabolic syndrome, abdominal obesity, and
family history of premature CVD according to ESH 2007
definition5 of CVRFs;
4. glomerular filtration rate categorization, microalbuminuria,
proteinuria, and CKD definitions according to the National
Kidney Foundation9;
5. overweight and obesity according to criteria established by
the fifth European Joint Task Force on Cardiovascular
Disease Prevention10;
6. salt consumption will be estimated using the renal excretion
of sodium measured in a valid 24-hour urine collection;
7. pulse wave velocity and central BP will be measured using
the Sphygmocor device (AtCor Medical Pty Ltd, New South
Wales, Australia) and calibrated using the individual’s sitting
brachial BP;
8. the definition of hypertension, diabetes, CKD, microalbu-
minuria, or proteinuria will respect the existence of 2
agreeing measurements taken at least 3 months apart; and
9. cognitive function evaluation and cutoff definitions were
done using different tools, as detailed elsewhere,11 and
allowing for the analysis of global, executive, and
memory functions.
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Research Team
A team of 88 researchers (medical doctors, cardiopneu-
mology technicians, psychologists, and nurses) was assembled
to observe the subjects and collect the data. A software tool was
built to function as an electronic case record form, containing
prevalidated and standardized questions and/or compulsory re-
cording items to all the subjects observed. All the researchers
involved were engaged in training sessions before beginning
subject’s observation, and standardization of procedures, mea-
surements, and recording were ensured. A calendar of activities
was designed to be followed for 2 years (86 observation dates).
Subject’s Observations
Every subject was considered as enrolled after his/her family
doctor had contacted him/her and was explained the study goals
and procedures, and provided a signed written consent form.
Subjects are to be observed twice at their PCHCC, on Saturday
mornings (the 2 observations are programmed to occur at least
3 months apart).
Whenever the team of researchers was scheduled to visit a
particular PCHCC, the enrolled subjects were contacted by tele-
phone during the preceding week, remembering the time schedule
and instructing them to bring their prescribed medication, to ob-
serve fasting for at least 8 hours (including alcohol and caffeine/
caffeinated beverages), and to refrain from smoking until clinical
evaluation, BP measurement, and blood/urine samples collection
were finished. All the data/all subject observations were collected/
performed in the morning, following the same protocol during the
entire study period.
At their first visit, subjects were submitted to a clinical interview
collecting information regarding relevant socioeconomic, clinical,
and family information; clinical parameters measurementVweight,
height, abdominal perimeter, and BP (3 measurements in optimal
conditions); PWVand central BP measurements (using Sphygmocor
device); electrocardiogram; and biologic specimen collectionVblood
and occasional urine samples (Fig. 1).
At their second visit, subjects were asked to repeat the clin-
ical parameters measurement (above described), collect biological
specimen: blood and occasional and 24-hour urine samples, and
perform a neurocognitive evaluation (in individuals 950 years
of age). Prescription drugs were once more recorded for every
participant (Fig. 2).
Follow-up information will be gathered through contact
with the subjects themselves and through their family doctors,
as scheduled and previewed in the written consent form. Sub-
jects older than 50 years, and after providing written consent,
will be invited to perform a brain magnetic resonance imaging
study, as a supplementary evaluation.
Central Laboratory Workup
All the collected blood and urine samples (occasional and
24-hour collections) will be processed in 1 central laboratory
(the Clinical Pathology Department of the Centro Hospitalar
do Alto Ave), ensuring standardized measurement techniques
and result outputs. On the week preceding each evaluation, a kit
containing prelabeled collection tubes was produced for every
subject to be evaluated on the upcoming Saturday. Upon arrival,
blood and urine samples were processed, and plasma, serum,
and urine samples of each participant (in each visit) were frozen
and subsequently stored at j82-C, allowing for the progressive
edification of a sample bank.
Statistical Analysis
All the collected information will be included in a database
that will be subjected to a predefined statistical analysis to
provide answers to the initial queries. The database was cons-
tructed in due respect of the national and international guidelines
to ensure the protection of the clinical data. This cross-sectional
study will be based on a representative sample collected by
stratified random sampling from the database comprising all the
subjects listed in all the health centers of the 2 cities, comprising a
total of 183,146 citizens. Prevalence of different studied charac-
teristics will be estimated and calculated by demographic char-
acteristics (age group, sex, education level) and RFs. The resulting
database will be a very large one, comprising more than 2 million
cells. Statistical data analysis will explore the associations be-
tween variables, using regression models so that predictive
models can be built for the relevant variables. Moreover, similar-
ities between subjects will be studied so that the possible existence
of clusters can be identified. Also, other multivariate analysis,
such as principal component analysis will be studied.
RESULTS
Of the 4000 subjects randomly selected, 3038 accepted to
participate in the study. During the last 2 years, they have been
observed according to the established and already described plan.
A team of 88 researchers from 17 different clinical institutions
performed more than 5580 patient observations, blood and urine
sample collections, and predetermined examinations (electrocar-
diogram, PWV, central BP), including 1047 cognitive evaluations
(in subjects 950 years of age). A biobank, containing more than
10,000 samples of plasma, 10,000 samples of serum, and 5000
samples of urine, is appropriately accommodated in our Univer-
sity. In Supplemental Table 3 (Supplemental Digital Content 1,
http://links.lww.com/JIM/A21), the number of subjects observed,
distributed by gender and age strata are presented for visits 1 and 2.
DISCUSSION
CVRFs and CVD in Portugal
Portugal is the only Western European state in the top
10 countries of the world where stroke exceeds ischemic heart
disease’s (IHD’s) standardized mortality rate.12 The incidence of
transient ischemic attacks and stroke is known to be very high in
Portugal and particularly in the northern region (up to 3 strokes
and 0.67 TIAs per year/1000 inhabitants13,14). Ischemic heart
disease has a complete different pattern of incidence in Portu-
gal; the country bears the second lowest standard mortality rate
by IHD in Europe15 and a particular geographic pattern of dis-
tribution of its incidence,16 with the northern coastal area re-
cording the lowest admission and mortality ratesVdata that
enhance the contrast with stroke incidence. With the strict CVR
phenotyping methodology here presented, we aspire to uncover
unclear contributions to this paradoxical CVD manifestation.
The prevalence of different CVRFs and the incidence of
CV events (CVEs) in the Portuguese population have received
greater attention in the last decade. Studies with different mea-
surement and population sampling methodologies have found
a national prevalence of hypertension ranging from 41.2%
to 42.6%,17Y19 with the diagnosis of isolated systolic hyper-
tension estimated to affect 34.7% of Portuguese individuals
older than 55 years20 and prehypertension afflicting 39.5% of
the adult population.17 However, the use of BP values measured
in a single visit and the recruitment strategies used raised criti-
cisms, arguing an overestimation of hypertension prevalence
and/or underestimation of its awareness and treatment rates.
Overestimation of hypertension and mean BP values with single
visit strategies have been reported21Y23 (ranging from 12.6% to
35% for hypertension in Portugal). Surprisingly, the number of
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studies using at least a 2-visit strategy is very scarce world-
wide.24,25 The prevalence, awareness, treatment, and control
rates of hypertension in Portugal are not different from those in
other southern and western European countries.25 The paradox
lies on the concept that the Portuguese hypertension prevalence
as well as BP mean values have been trending down in the last
decades,26 at a rate that is reported to be superior to that observed
in other Western European countries,27 and still the incidence of
CVE and particularly stroke has kept disproportionally elevated,
even if presenting a tendency to decline.28,29 We aim to produce
more precise estimation of BP levels and hypertension prevalence
as well as the quantification of overestimation of BP and hyper-
tension that results from single BP evaluation (with the conse-
quent underestimation of BP treatment and control).
Other CVRFs have been less studied in Portugal. The world-
wide trend in mean fasting plasma glucose (FPG) has slowly in-
creased, and the age-standardized prevalence of diabetes ranges
from 9.8% in men to 9.2% in women.30 Portuguese estimations of
the prevalence of diabetes (single visit strategy) range from 11.7%
to 13% of the adult population,31,32 evidencing a higher preva-
lence of the disease than globally recorded, especially concerning
men; the prevalence of prediabetes was estimated in 23.3%.31
According to the International Diabetes Federation, the preva-
lence of diabetes in Portugal was the highest recorded in the
European countries analyzed.33 We could not find any national
trend analysis of diabetes and FPG levels. The relevance of mean
FPG levels increases with evidence linking growing levels with
CVD, independently of the existence of diabetes.
Chronic kidney disease and microalbuminuria are well rec-
ognized CVR factors.34Y37 An estimation of CKD (based on a
single measurement of serum creatinine levels and on information
from a national registry of patients under renal replacement therapy)
reported a 6.1% prevalence in the Portuguese adult inhabitants,38
similar to reports in other European countries.39 However, more
FIGURE 1. Study procedures outline (visit 1).
FIGURE 2. Study procedures outline (visit 2).
Cunha et al Journal of Investigative Medicine & Volume 62, Number 5, June 2014
816 * 2014 The American Federation for Medical Research
Copyright © 2014 American Federation for Medical Research. Unauthorized reproduction of this article is prohibited.
accurate methods of staging CKD have been established, com-
bining glomerular filtration rate estimates and albuminuria40,41
and exhibiting a better association both to the risk of progression
to end-stage renal disease and to the CVR in the population,
throughout all age classes.10,42,43 Therefore, a more accurate
definition of CKD prevalence in Portugal, using both markers, is
missing. Only for Portuguese hypertensive subjects44 can a report
of prevalence of microalbuminuria (24%) be found.
Regarding dyslipidemia, a systematic review of the literature
found several difficulties in aggregating results from different
studies in Portugal, with different population groups, measure-
ment methodologies, selection bias, and cutoff values.45Y47 Main
extractable results revealed mean serum total cholesterol values
greater than 200 mg/dL, 20% of the population recording choles-
terol levels greater than 240 mg/dL, and low high-density lipopro-
tein and high triglyceride levels affecting 25% and 30.7% of the
population, respectively.48 In Portuguese subjects treated with
statins, 68% and 62.9% did not have their total cholesterol and low-
density lipoprotein cholesterol levels controlled, respectively.49
Worldwide, a slow and small global trend of decreasing levels of
total cholesterol has been recorded in the last 3 decades, estimating
current mean levels in Western Europe as 212.7 mg/dL.50
Metabolic syndrome has been estimated to afflict 27.5%
of the national population and 23.9% of a regional urban sample
of adult dwellers48,51; male sex was predominantly presenting
the syndrome from 18 to 49 years, with females being more
afflicted in older age groups.48 Overweight and obesity preva-
lence are also growing in the Portuguese population, with a
composite prevalence of 66.6% and 57.9% for men and women,
respectively.52,53
In summary, we believe that it is important to look simul-
taneously at strictly determined BP and FPG mean values, lipid
serum levels, estimated glomerular filtration rate, and albu-
minuria when trying to understand the different CVE rates
registered in Portugal (more stroke than IHD), and to look for
other explanations of these same CVE that go beyond individ-
ual prevalence of hypertension, diabetes, and CKD (cumulative
RFs, intermediate CV phenotypes, CV risk reclassification
strategiesVglobal CVR stratification).
Recent Concepts of Cardiovascular Risk and CVD
New methods of evaluating CVD and CVR have been
proposed. Measurement of arterial stiffness (through PWV) has
been accepted as portraying the reflex of different CVRFs in the
arterial structure, becoming itself a marker of CVR with inde-
pendent predictive power of CVE beyond and above traditional
CVRFs, allowing for risk restratification of significant pro-
portions of the population; the predictive ability of arterial
stiffness is higher in high-risk groups, but it retains its dis-
criminative power both in the general population and hyper-
tensive subjects independently of age.54Y56 Recent European
guidelines establish PWV values greater than 10 m/s as TOD,57
and reference values for the European population have been
published.58
In Portugal, arterial stiffness has been raising growing in-
terest. In a pioneer study, a concurrent determination of salt
intake and PWV in a convenience sample of 426 subjects could
record a high salt intake and its independent correlation with
PWV values (r = 0.256, after adjustment for age and BP).59
Another project has determined PWV values to subjects re-
ferred by their clinicians to 3 clinical centers60; a predictive
value of PWV for CVE could be defined for values of PWV
greater than the 95th percentile. Interestingly, the unadjusted
risk ratio for stroke was 6.68, and that for myocardial infarc-
tion was 5.4. In a subsample of 668 young subjects (mean age,
40 years) with low CV risk and significant male predominance
(60%), the authors statistically extrapolated ‘‘normal’’ PWV
values for 16 different age classes (8 per sex).61
Central blood pressure and central hemodynamic indexes
are another aspect of vascular evaluation that can be determined
safely and noninvasively. Its association with the development
of TOD and CVD has been well documented.62 A recent meta-
analysis has established their values as independent predictors
of CVE and all-cause mortality,63 and interest has been in-
creasing as CBP is thought to better reflect the pressure load
sustained by vascular circulation of the brain, kidney, and cor-
onary arteries.64Y67
Early vascular aging is a functional and clinical concept68
in fast development: the normal age-dependent process of vas-
cular change in structure and function can, in susceptible sub-
jects or under the influence of different factors (including
CVRFs), be accelerated and/or be replaced by a pathologic
process of vascular remodeling, leading to premature athero-
sclerosis and CVD.69Y73 The definition of EVA is dependent on
arterial stiffness measurements, but debate is ongoing to better
refine the criteria to use. The question remains if by identifying
subjects with early vascular changes, one could reclassify low
CV risk subjects in higher CV risk classes and treat early and
more intensively to prevent CVD.72,74 No evaluation of EVA,
PWV, or CBP has ever been attempted in the Portuguese pop-
ulation. The CVR reclassification value of these variables in the
Portuguese CVD setting is something we aim to establish with
the current study.
Vascular Aging and Brain Aging
Subclinical organ damage is one important parameter to
classify subjects concerning their total CVR. The brain is par-
ticularly challenging (when it comes down to evaluate TOD
induced by CVRFs or CVD) as there is no simple way to
identify subjects with subclinical manifestations, and TOD is
defined only when a documented cerebrovascular event has
been registered. Much has been debated concerning the influ-
ence and contribution of vascular disease, CVRFs, or hemo-
dynamic variables to the acceleration of the brain aging process
and/or the establishment of cognitive decline, and the concept
of vascular cognitive impairment is well established.75,76
With an aging population, progression to dementia and
the increase in the number of dependent subjects are clearly
a concern; estimation of the prevalence of mild cognitive
impairment ranges from 10% to 20% in adults older than
65 years,77 which obviates the need to early identification of
subjects at risk of cognitive decline and control of factors that
contribute to dementia. The LADIS (Leukoaraiosis and Dis-
ability) study78Y80 has shown that older independent subjects
with white matter hyperintensities progress to disability and
functional decline with the more severe changes relating to
higher risk of decline.78 An association of lacunar infarcts with
cognitive decline and white matter hyperintensities has also
been considered (hinting for a spectrum of different expression
of small vessel disease),79 and an independent effect of CVRFs
in cognitive decline has also been reported.80 In Portugal, the
prevalence of cognitive impairment has been studied in a re-
gional sample of the population, and a report of 12.0% to 16.8%
(urban-rural areas, respectively) has been described.81
Evidence fueling the merit of a precocious and preventive
identification of subjects at risk of progression to dementia or
cerebrovascular disease comes from the Framingham study,
where changes in white matter microstructure and reduction
in gray matter volume could be seen in association with grow-
ing levels of BP in young subjects.82 With the knowledge that
Journal of Investigative Medicine & Volume 62, Number 5, June 2014 Global Cardiovascular Risk and Disease
* 2014 The American Federation for Medical Research 817
Copyright © 2014 American Federation for Medical Research. Unauthorized reproduction of this article is prohibited.
arterial stiffness measurements can be associated and predict
cognitive decline83Y85 and silent cerebral small vessel disease,86
one could aspire to an early recognition of subjects at risk using
PWV measurement.
CONCLUSIONS
Here we reviewed the literature reporting the state of
knowledge concerning CVD, CVRF prevalence, and cognitive
decline estimates of the Portuguese population, comparing it
with what is known abroad. Based on this evidence, we devel-
oped the rationale of the Guimara˜es/Vizela Study, a multimodal
population-based cohort study to determine global CV risk and
disease, a comprehensive approach to determination of global
CV risk and risk reclassification perspectives, with the ultimate
goal of early detection of subjects at risk for CVD, renal disease,
cognitive impairment, and dementia.
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